Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.40 |
| ▸ | GGT1 | P19440 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | GNPAT | O15228 | 2/20 | 0.33 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227446 | 1.00 | NOD1 (0.40) | NOD1GGT1FOLH1GNPATOTC | |
| SCHEMBL14951121 | 0.85 | NOD1 (0.32) | NOD1 | |
| SCHEMBL468949 | 0.85 | KISS1R (0.36) | NOD1 | |
| SCHEMBL14614152 | 0.84 | NOD1 (0.31) | NOD1 | |
| SCHEMBL25660783 | 0.83 | ALDH1A1 (0.36) | NOD1FOLH1 | |
| SCHEMBL25662433 | 0.83 | NOD1 (0.35) | NOD1GGT1FOLH1GNPAT | |
| SCHEMBL22359335 | 0.82 | GNPAT (0.50) | NOD1FOLH1GNPAT | |
| SCHEMBL10142404 | 0.81 | GGT1 (0.39) | NOD1GGT1FOLH1GNPAT | |
| SCHEMBL20012343 | 0.81 | NOD1 (0.37) | NOD1GGT1FOLH1GNPATOTC | |
| SCHEMBL22100977 | 0.80 | KISS1R (0.44) | NOD1FOLH1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | ALCON RESEARCH, LTD. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | NOD1 577/4885GGT1 3820/4885FOLH1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.